Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Blood20.30
Volume: 132, Issue: Supplement 1, Pages: 255 - 255
Published: Nov 29, 2018
Abstract
Introduction: Salvage autologous transplantation (sASCT) in multiple myeloma has been shown to induce superior durability of responses over low-dose alkylating consolidation therapy in the relapsed setting1. The optimum re-induction regimen leading to sASCT is yet to be defined though a combination of a proteasome inhibitor (PI) and immunomodulatory agent (IMiD) is likely to offer the best depth of response. UK-MRA Myeloma XII (ACCoRD study)...
Paper Details
Title
Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial
Published Date
Nov 29, 2018
Journal
Volume
132
Issue
Supplement 1
Pages
255 - 255
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.